Talviraline

Drug Profile

Talviraline

Alternative Names: Bay 10-8979; HBY 097

Latest Information Update: 29 Jun 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aventis; Bayer
  • Developer Bayer
  • Class Antiretrovirals
  • Mechanism of Action RNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued HIV-1 infections

Most Recent Events

  • 29 Jun 2000 Discontinued-II for HIV-1 infections in Germany (PO)
  • 25 Feb 2000 Discontinued-II for HIV-1 infections in USA (PO)
  • 16 Apr 1999 A phase II study has been added to the therapeutic trials and adverse events sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top